ReGen has the following major commercial objectives:-
- The development of the markets for nutraceutical products based on the ColostrininTM peptide complex.
- The development of the constituent peptides within the Colostrinin™ complex as prospective pharmaceutical candidates
- To develop novel pharmaceutical formulations of zolpidem for the treatment of brain dormancy.
The natural origin and nature of the Colostrinin™ complex means that it conforms to the general criteria for non-pharmaceutical health supplements. ReGen signed its first deal to commercialise ColostrininTM as a nutraceutical with Metagenics Inc., who began to sell the product under the brand name of CogniSureTM in North America and Australasia in July 2007. In March 2008, the Company announced that it had signed the first European distribution agreement for ColostrininTM with Golgi Pharmaceuticals Ltd of Cyprus. Further agreements have since been signed with distributors in Greece, Turkey and the Balkans, Poland and the United Kingdom. Discussions with potential licensing partners in other areas of the world are ongoing.
The possibility for a nutraceutical targeted at domestic dogs and cats has also been investigated and ReGen conducted a study in 2007 at a UK-based veterinary practice. The encouraging results of that study showed that Colostrinin™ could significantly reduce the symptoms of cognitive dysfunction in aged cats and dogs. The Company is seeking industry partners to continue the development of this project.
The Company has continued to develop the pharmaceutical potential of Colostrinin™ by carrying out pre-clinical studies at the University of Texas Medical Branch (UTMB) on the constituent peptides of the Colostrinin™ complex. Peptide activity in genes connected with the regulation of Alzheimer’s disease, obesity, hypertension and asthma has been discovered. Discussions are currently proceeding as to how this project may be taken forward.
ReGen released findings of its own clinical study on zolpidem in South Africa in August 2007, the results of which showed clear evidence that a spray is absorbed faster and more completely than tablets and that a dose of 2.5mg caused no more sedation than placebo, suggesting the possibility that repeated 2.5mg spray doses will show efficacy without undue sedation. Based on these results, ReGen is reviewing options to continue the development of novel zolpidem formulations for the treatment of brain dormancy. Most recently a completely independent study at the University of Pretoria, South Africa, reported to the market in November 2009, gave further evidence of the activity of zolpidem in this area.
ReGen is also interested in sourcing new business opportunities by securing development rights to commercially interesting projects and through the acquisition of individual companies whose assets or business show potential for future success. The ReGen management have reviewed a number of prospective targets in the past and will continue to be active in this area in the future.
